TLX1 and malignant colon neoplasm: Therefore, we validated the performance of the GALR1, TLX1, and ZNF154 markers in independent sets of Illumina 450 K methylation array data available for four cancer types: breast cancer (450 tumors, 149 normal samples), colon cancer (35 tumors, 18 normal samples), lung adenocarcinoma (9 tumors, 11 normal samples), and prostate adenocarcinoma (31 tumors, 16 normal samples).